Close
Close

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

Access Programs

Disease Information

Descriptive Information
Brief Title † Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Official Title † Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
Brief Summary This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Detailed Description This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Study Phase N/A
Study Type † Observational
Study Design † Observational Model: Cohort, Time Perspective: Prospective
Primary Outcome Measure † Hepatorenal syndrome
Secondary Outcome Measure † Mortality
Condition † Hepatorenal Syndrome
Intervention †
Study Arms / Comparison Groups Hepatorenal syndrome group Patients with advanced cirrhosis who develope hepatorenal syndrome Non-hepatorenal syndrome group Patients with advanced cirrhosis who do not hepatorenal syndrome
Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status †
Estimated Enrollment † 100
Start Date † July 2012
Completion Date June 2017
Primary Completion Date June 2015
Eligibility Criteria † Inclusion Criteria: - Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation - Willing to give informed consent Exclusion Criteria: - Patients with co-existing renal diseases
Gender Both
Ages 18 Years - 90 Years
Accepts Healthy Volunteers No
Contacts †† Desmond Yap, MD, 85222553879, desmondy@hku.hk
Location Countries † Hong Kong
Administrative Information
NCT ID † NCT02434445
Organization ID UW12342
Secondary IDs ††
Responsible Party Principal Investigator
Study Sponsor † The University of Hong Kong
Collaborators †† The Hong Kong Society of Nephrology
Investigators † Principal Investigator: Desmond Yap, MD, The University of Hong Kong
Information Provided By
Verification Date April 2015
First Received Date † April 30, 2015
Last Updated Date April 30, 2015
† Required WHO trial registration data element.
†† WHO trial registration data element that is required only if it exists.
Find a Clinical Trial
Trending videos
by Abidemi Uruejoma
29,240 views
by Christine DuBois
23,790 views
by Abidemi Uruejoma
21,620 views
Free Newsletter